• Imunon will host an investor R&D Day on Sept. 23, 2026, in New York City.
• Event will focus on the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
• Presentations will cover recent clinical developments, trial progress, upcoming milestones, and Phase 2 MRD work with Break Through Cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260830PRIMZONEFULLFEED9816265) on August 26, 2026, and is solely responsible for the information contained therein.